Research for the key factors affecting the occurrence of postherpetic neuralgia based on major data analysis

注册号:

Registration number:

ITMCTR1900002436

最近更新日期:

Date of Last Refreshed on:

2019-06-30

注册时间:

Date of Registration:

2019-06-30

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于大数据分析影响带状疱疹后遗神经痛发生之关键因素的研究

Public title:

Research for the key factors affecting the occurrence of postherpetic neuralgia based on major data analysis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于大数据分析影响带状疱疹后遗神经痛发生之关键因素的研究

Scientific title:

Research for the key factors affecting the occurrence of postherpetic neuralgia based on major data analysis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

四川省科技厅重点研发项目2018FZ0060

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900024216 ; ChiMCTR1900002436

申请注册联系人:

李天浩

研究负责人:

李天浩

Applicant:

Tianhao Li

Study leader:

Tianhao Li

申请注册联系人电话:

Applicant telephone:

+86 13880986337

研究负责人电话:

Study leader's telephone:

+86 13880986337

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

52454170@qq.com

研究负责人电子邮件:

Study leader's E-mail:

52454170@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川省成都市温江区柳台大道1166号

研究负责人通讯地址:

四川省成都市温江区柳台大道1166号

Applicant address:

1166 Liutai Avenue, Wenjiang District, Chengdu, Sichuan, China

Study leader's address:

1166 Liutai Avenue, Wenjiang District, Chengdu, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都中医药大学

Applicant's institution:

Chengdu University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013/8/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都中医药大学

Primary sponsor:

Chengdu University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

四川省成都市温江区柳台大道1166号

Primary sponsor's address:

1166 Liutai Avenue, Wenjiang District, Chengdu, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

成都中医药大学附属医院

具体地址:

中国四川省成都市十二桥路39号(610072)

Institution
hospital:

Hospital of Chengdu University of Traditional Chinese Medicine

Address:

39 Shi-er-qiao Road, Chengdu, Sichuan

经费或物资来源:

四川省科技厅重点研发项目2018FZ0060

Source(s) of funding:

Science and Technology Department of Sichuan Province key research and development project 2018FZ0060

研究疾病:

带状疱疹后遗神经痛

研究疾病代码:

Target disease:

Postherpetic Neuralgia

Target disease code:

研究类型:

Study type:

基础科学研究

Basic Science

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

其它

Others

研究目的:

通过数据分析,了解导致带状疱疹后遗神经痛发生的关键因素和预防带状疱疹后遗神经痛的关键治疗手段。

Objectives of Study:

To find the key factors leading to the occurrence of postherpetic neuralgia and the key treatment methods preventing postherpetic neuralgia were understood by data analysis.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.2012年1月至2017年4月期间成都中医药大学附属医院皮肤科住院病人 2.第一诊断为带状疱疹或带状疱疹后遗神经痛

Inclusion criteria

1. From January 2012 to April 2017, the dermatology inpatients in the hospital of chengdu university of traditional Chinese medicine; 2. The first diagnosis was herpes zoster or postherpetic neuralgia

排除标准:

Exclusion criteria:

No

研究实施时间:

Study execute time:

From 2018-01-01

To      2019-12-31

征募观察对象时间:

Recruiting time:

From 2019-07-01

To      2019-11-30

干预措施:

Interventions:

组别:

未发生带状疱疹后遗神经痛

样本量:

732

Group:

No postherpetic neuralgia occurred

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

组别:

发生带状疱疹后遗神经痛

样本量:

571

Group:

Postherpetic neuralgia occurs

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

样本总量 Total sample size : 1303

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川

市(区县):

Country:

China

Province:

Sichuan Province

City:

单位(医院):

成都中医药大学附属医院

单位级别:

三级甲等医院

Institution/hospital:

Hospital of Chengdu University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

Blood routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

凝血功能

指标类型:

主要指标

Outcome:

coagulation function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

西药

指标类型:

主要指标

Outcome:

Western medicine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

梅毒、艾滋、乙肝定性

指标类型:

主要指标

Outcome:

syphilis antibody, AIDS antibody Qualitative analysis of and hepatitis b

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

饮食要求

指标类型:

次要指标

Outcome:

Dietary requirements

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

非药物治疗方法

指标类型:

主要指标

Outcome:

Non-drug therapy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中药

指标类型:

主要指标

Outcome:

Chinese medicine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

护理级别

指标类型:

次要指标

Outcome:

Nursing level

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

小便常规

指标类型:

主要指标

Outcome:

Urine Routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝肾功能

指标类型:

主要指标

Outcome:

hepatorenal function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

大便常规

指标类型:

主要指标

Outcome:

Stool Routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

电解质

指标类型:

主要指标

Outcome:

electrolyte

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂

指标类型:

主要指标

Outcome:

blood lipid

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体液免疫

指标类型:

主要指标

Outcome:

humoral immunity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

护理常规

指标类型:

次要指标

Outcome:

nursing routine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

粪便

组织:

Sample Name:

Excrement

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

日期:2019年12月31日 方式:以论文附件方式共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Date: December 31, 2019 Method: Share by attachment of the paper

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子病历系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Medical Record

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above